A large, long-term study led by an Albert Einstein College of Medicine researcher has found that the introduction of the ...
The first vaccines, approved in 2006, protects against four strains, HPV-6, HPV-11, HPV-16 and HPV-18. Another, approved in ...
Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...
BUFFALO, N.Y. — On Tuesday, Roswell Park Comprehensive Cancer Center celebrated the reopening of one of its cancer treatment centers following an expansion. The Head & Neck Surgery, Plastic Surgery, ...
Two new exploratory studies of radioenhancers used in combination with radiation therapy in the treatment of head and neck cancers showed that these agents can boost the effectiveness of radiotherapy ...
In the first evidence of its kind, Artera developed and validated a new MMAI biomarker for head and neck cancer in just five months, a testament to the speed and rigor of the Artera platform to ...
The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...
The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback